Published in J Thromb Haemost on August 01, 2004
Thrombotic, Inflammatory & Gene Markers of CVD in Women | NCT00006539
Inflammation, Infection, and Future Cardiovascular Risk | NCT00005496
C-reactive protein and venous thromboembolism. A prospective investigation in the ARIC cohort. Thromb Haemost (2009) 1.11
High-sensitivity C-reactive protein is not a risk factor for venous thromboembolism: the Tromso study. Haematologica (2011) 0.81
The utility of C-reactive protein in the detection of atherothrombotic vascular disease: ready for prime time? J Thromb Haemost (2004) 0.75
Serum C-reactive protein increases the risk of venous thromboembolism: a prospective study and meta-analysis of published prospective evidence. Eur J Epidemiol (2017) 0.75
C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA (2001) 15.85
Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease. N Engl J Med (1996) 8.57
Prevalence of Alzheimer's disease in a community population of older persons. Higher than previously reported. JAMA (1989) 8.36
Long-term weight loss and changes in blood pressure: results of the Trials of Hypertension Prevention, phase II. Ann Intern Med (2001) 5.90
Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA (2001) 5.54
Baseline characteristics of participants in the Women's Health Study. J Womens Health Gend Based Med (2000) 4.84
Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin Pharmacol Ther (2008) 4.54
Beta-carotene supplementation and incidence of cancer and cardiovascular disease: the Women's Health Study. J Natl Cancer Inst (1999) 4.27
Self-reported breast implants and connective-tissue diseases in female health professionals. A retrospective cohort study. JAMA (1996) 3.69
Physical activity and coronary heart disease in women: is "no pain, no gain" passé? JAMA (2001) 3.65
Variability and classification accuracy of serial high-sensitivity C-reactive protein measurements in healthy adults. Clin Chem (2001) 3.12
Prevention Conference V: Beyond secondary prevention: identifying the high-risk patient for primary prevention: noninvasive tests of atherosclerotic burden: Writing Group III. Circulation (2000) 2.94
Novel clinical markers of vascular wall inflammation. Circ Res (2001) 2.80
Inflammatory bio-markers and cardiovascular risk prediction. J Intern Med (2002) 2.70
Proposed cardiovascular risk assessment algorithm using high-sensitivity C-reactive protein and lipid screening. Clin Chem (2001) 2.67
A prospective study of incident comprehensive medical home care use among the elderly. Am J Public Health (1988) 2.67
The primary prevention of myocardial infarction. N Engl J Med (1992) 2.63
Blood pressure and inflammation in apparently healthy men. Hypertension (2001) 2.55
Effect of marathon running on inflammatory and hemostatic markers. Am J Cardiol (2001) 2.50
Clinical efficacy of an automated high-sensitivity C-reactive protein assay. Clin Chem (1999) 2.35
Discordance between meta-analyses and large-scale randomized, controlled trials. Examples from the management of acute myocardial infarction. Ann Intern Med (1995) 2.31
Correlates of cognitive function in an elderly community population. Am J Epidemiol (1988) 2.26
Weight loss intervention in phase 1 of the Trials of Hypertension Prevention. The TOHP Collaborative Research Group. Arch Intern Med (1993) 2.26
The pravastatin inflammation CRP evaluation (PRINCE): rationale and design. Am Heart J (2001) 2.12
Periodontal disease and risk of subsequent cardiovascular disease in U.S. male physicians. J Am Coll Cardiol (2001) 2.11
A retrospective cohort study of cigarette smoking and risk of rheumatoid arthritis in female health professionals. Arthritis Rheum (1999) 2.09
Low-dose aspirin for migraine prophylaxis in women. Cephalalgia (2001) 2.07
High-sensitivity C-reactive protein: a novel and promising marker of coronary heart disease. Clin Chem (2001) 2.06
Cystatin C deficiency in human atherosclerosis and aortic aneurysms. J Clin Invest (1999) 2.03
HbA1c measured in stored erythrocytes and mortality rate among middle-aged and older women. Diabetologia (2007) 2.03
Migraine, headache, and the risk of stroke in women: a prospective study. Neurology (2005) 2.01
Absence of diurnal variation of C-reactive protein concentrations in healthy human subjects. Clin Chem (2001) 2.01
Association of common CRP gene variants with CRP levels and cardiovascular events. Ann Hum Genet (2005) 2.00
Large-scale trials of thrombolytic therapy for acute myocardial infarction: GISSI-2, ISIS-3, and GUSTO-1. Ann Intern Med (1993) 1.97
Cost effectiveness of thrombolytic therapy with streptokinase in elderly patients with suspected acute myocardial infarction. N Engl J Med (1992) 1.92
Blood pressure measurement in childhood epidemiological studies. Circulation (1995) 1.83
Adult height and incidence of cancer in male physicians (United States). Cancer Causes Control (1997) 1.76
Left ventricular hypertrophy and morphology in familial hypertrophic cardiomyopathy associated with mutations of the beta-myosin heavy chain gene. J Am Coll Cardiol (1993) 1.68
Novel inflammatory markers of coronary risk: theory versus practice. Circulation (1999) 1.65
Lack of association of C-reactive protein and coronary calcium by electron beam computed tomography in postmenopausal women: implications for coronary artery disease screening. J Am Coll Cardiol (2000) 1.62
D-dimer, factor VIII coagulant activity, low-intensity warfarin and the risk of recurrent venous thromboembolism. J Thromb Haemost (2006) 1.62
Height and incidence of cardiovascular disease in male physicians. Circulation (1993) 1.62
Multi-locus candidate gene polymorphisms and risk of myocardial infarction: a population-based, prospective genetic analysis. J Thromb Haemost (2006) 1.61
Does weight loss from middle age to old age explain the inverse weight mortality relation in old age? Am J Epidemiol (1995) 1.60
Prospective evaluation of the angiotensin-converting enzyme insertion/deletion polymorphism and the risk of stroke. Circulation (1999) 1.57
Change in pulmonary function in children associated with air pollution episodes. J Air Pollut Control Assoc (1982) 1.55
Survey of C-reactive protein and cardiovascular risk factors in apparently healthy men. Am J Cardiol (1999) 1.54
Soluble CD40L and cardiovascular risk in women. Circulation (2001) 1.52
Angiotensinogen genotype, sodium reduction, weight loss, and prevention of hypertension: trials of hypertension prevention, phase II. Hypertension (1998) 1.51
Obesity and renal cell cancer--a quantitative review. Br J Cancer (2001) 1.51
Surgical management of carcinoid heart disease. Ann Thorac Surg (1991) 1.50
Do atherosclerosis and type 2 diabetes share a common inflammatory basis? Eur Heart J (2002) 1.45
A prospective evaluation of the interleukin-1 receptor antagonist intron 2 gene polymorphism and the risk of myocardial infarction. Thromb Haemost (2001) 1.45
Qualitative and quantitative effects of APOE genetic variation on plasma C-reactive protein, LDL-cholesterol, and apoE protein. Genes Immun (2006) 1.44
Usefulness of visceral obesity (waist/hip ratio) in predicting vascular endothelial function in healthy overweight adults. Am J Cardiol (2001) 1.44
Mutation in the promoter region of the beta-fibrinogen gene and the risk of future myocardial infarction, stroke and venous thrombosis. Eur Heart J (2001) 1.44
A secondary prevention trial of antioxidant vitamins and cardiovascular disease in women. Rationale, design, and methods. The WACS Research Group. Ann Epidemiol (1995) 1.44
Should survivors of myocardial infarction with low ejection fraction be routinely referred to arrhythmia specialists? JAMA (1996) 1.39
Factor V Leiden and recurrent venous thromboembolism. Thromb Haemost (1996) 1.39
A prospective evaluation of lipoprotein-associated phospholipase A(2) levels and the risk of future cardiovascular events in women. J Am Coll Cardiol (2001) 1.38
A polymorphism in the VKORC1 regulator calumenin predicts higher warfarin dose requirements in African Americans. Clin Pharmacol Ther (2010) 1.35
Circulating cell adhesion molecules are correlated with ultrasound-based assessment of carotid atherosclerosis. Arterioscler Thromb Vasc Biol (1998) 1.32
Inflammation, infection, and cardiovascular risk: how good is the clinical evidence? Circulation (1998) 1.31
Genetic variation in alcohol dehydrogenase and the beneficial effect of moderate alcohol consumption on myocardial infarction. N Engl J Med (2001) 1.30
Identifying children at high risk for the development of essential hypertension. J Pediatr (1993) 1.26
Aspirin in the primary prevention of angina pectoris in a randomized trial of United States physicians. Am J Med (1990) 1.25
Lipid levels and the risk of ischemic stroke in women. Neurology (2007) 1.23
Differential leucocyte count and the risk of future coronary artery disease in healthy men and women: the EPIC-Norfolk Prospective Population Study. J Intern Med (2007) 1.22
Feasibility and efficacy of sodium reduction in the Trials of Hypertension Prevention, phase I. Trials of Hypertension Prevention Collaborative Research Group. Hypertension (1993) 1.22
Ability of VKORC1 and CYP2C9 to predict therapeutic warfarin dose during the initial weeks of therapy. J Thromb Haemost (2009) 1.22
Migraine and biomarkers of cardiovascular disease in women. Cephalalgia (2007) 1.21
Comparison of self-reported diagnosis of connective tissue disease with medical records in female health professionals: the Women's Health Cohort Study. Am J Epidemiol (1999) 1.19
Low-dose aspirin and breast cancer risk: results by tumour characteristics from a randomised trial. Br J Cancer (2008) 1.14
Influence of genetic variation in the C-reactive protein gene on the inflammatory response during and after acute coronary ischemia. Ann Hum Genet (2006) 1.14
Factor V Leiden mutation and the risks for thromboembolic disease: a clinical perspective. Ann Intern Med (1997) 1.13
Prevention Conference V: Beyond secondary prevention: identifying the high-risk patient for primary prevention: medical office assessment: Writing Group I. Circulation (2000) 1.13
Hypertension and borderline isolated systolic hypertension increase risks of cardiovascular disease and mortality in male physicians. Circulation (1997) 1.11
Sodium reduction for hypertension prevention in overweight adults: further results from the Trials of Hypertension Prevention Phase II. J Hum Hypertens (2005) 1.08
Moderate alcohol consumption and the risk of sudden cardiac death among US male physicians. Circulation (1999) 1.08
Physical activity and breast cancer risk: the Women's Health Study (United States). Cancer Causes Control (2001) 1.08
Early versus delayed angiotensin-converting enzyme inhibition therapy in acute myocardial infarction. The healing and early afterload reducing therapy trial. Circulation (1997) 1.08
Repair of truncus arteriosus in the neonate. J Thorac Cardiovasc Surg (1993) 1.07
Relationship of alcohol intake with blood pressure in young adults. Hypertension (1995) 1.07
C-reactive protein, inflammation, and coronary risk. Med Clin North Am (2000) 1.06
Plasma concentrations of interleukin-6 and abdominal aortic diameter among subjects without aortic dilatation. Arterioscler Thromb Vasc Biol (1999) 1.06
Lipid biomarkers, hormone therapy and the risk of venous thromboembolism in women. J Thromb Haemost (2009) 1.05
Plasma concentration of soluble vascular cell adhesion molecule-1 and subsequent cardiovascular risk. J Am Coll Cardiol (2000) 1.05
A comparison of elderly participants in a community survey with nonparticipants. Public Health Rep (1991) 1.04
Reproducibility and predictive values of routine blood pressure measurements in children. Comparison with adult values and implications for screening children for elevated blood pressure. Am J Epidemiol (1987) 1.04
Efficacy of nonpharmacologic interventions in adults with high-normal blood pressure: results from phase 1 of the Trials of Hypertension Prevention. Trials of Hypertension Prevention Collaborative Research Group. Am J Clin Nutr (1997) 1.04
Design and analysis methods for longitudinal research. Annu Rev Public Health (1983) 1.04
A prospective evaluation of the CD14 C(-260)T gene polymorphism and the risk of myocardial infarction. Atherosclerosis (2001) 1.03
Effects of ramipril on plasma fibrinolytic balance in patients with acute anterior myocardial infarction. HEART Study Investigators. Circulation (1997) 1.02